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Background: Multiparametric magnetic resonance imaging (mpMRI) of the prostate has excellent
sensitivity in detecting clinically significant prostate cancer (csPCa). Nevertheless, the clinical utility
of negative mpMRI (nMRI) is less clear.
Objective: To assess outcomes of men with nMRI and clinical follow-up after 7 yr of activity at a
reference center.
Design, setting, and participants: All mpMRI performed from January 2010 to May 2015 were
reviewed. We selected all patients with nMRI and divided them in group A (naïve patients) and
group B (previous negative biopsy). All patients without a diagnosis of PCa had aminimum follow-up
of 2 yr and at least two consecutive nMRI. Patients with positivempMRIwere also identified to assess
their biopsy outcomes.
Outcome measurements and statistical analysis: A Kaplan-Meier analysis was performed to assess
both any-grade PCa and csPCa diagnosis-free survival probabilities. Univariable and multivariable
Cox regression models were fitted to identify predictors of csPCa diagnosis.
Results and limitations: We identified 1545 menwith nMRI, and 1255 of them satisfied the inclusion
criteria; 659 belonged to group A and 596 to group B. Any-grade PCa and csPCa diagnosis-free survival
probabilities after 2 yr of follow-up were 94% and 95%, respectively, in group A; in group B, they were
96%. After 48 mo of follow-up, any-grade PCa diagnosis-free survival probability was 84% in group A
and 96% in group B (log rank p < 0.001). Diagnosis-free survival probability for csPCa was unchanged
after 48 mo of follow-up. On multivariable Cox regression analysis, increasing age (p = 0.005) was an
independent predictor of lower csPCa diagnosis probability, while increasing prostate-specific antigen
(PSA) and PSA density (<0.001) independently predicted higher csPCa diagnosis probability. The
prevalence of and positive predictive value for csPCa were 31.6% and 45.5%, respectively. Limitations
include limited follow-up and the inability to calculate true csPCa prevalence in the study population.
Conclusions: mpMRI is highly reliable to exclude csPCa. Nevertheless, systematic biopsy should be
recommended even after nMRI, especially in younger patients with high or raising PSA levels.
Patient summary: It is a matter of debatewhether patients with negative multiparametric magnetic
resonance imaging (mpMRI) of the prostate could obviate the need to perform a systematic biopsy. In
this report, we looked at the outcomes of patients with negativempMRI andmidterm clinical follow-
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The role of multiparametric magnetic resonance imaging
(mpMRI) in prostate cancer (PCa) management has been
constantly growing during the past decade. It is currently
recommended to target lesions in men suspected of
harboring PCa despite negative biopsies [1], and it is
increasingly being used to guide biopsies, thanks to the high
accuracy of mpMRI-targeted biopsy techniques [2,3]. None-
theless, a systematic use of mpMRI as a triage test in
patients with suspicion of PCa is still a matter of debate. The
rationale of such a strategy lies on the limitations of PCa
screening and diagnosis, which entails offering systematic
transrectal ultrasound-guided biopsy (SB) to men present-
ing high levels of serumprostate-specific antigen (PSA) and/
or a suspicious digital rectal examination (DRE). First, many
menwithout PCa manifest elevated PSA levels and undergo
unnecessary biopsies, which often detect clinically insig-
nificant cancers [4]. In addition, SB may miss up to 20% of
cancers [5]. Repeat biopsies are often needed to establish
the diagnosis, but they can lead to overdetection and
overtreatment of insignificant cancers, with a limited
detection rate [6]. On the contrary, the risk of missing
clinically significant PCa (csPCa) with SB may turn into
undertreatment when active surveillance (AS) is considered
[7]. In this context, mpMRI is potentially enticing as a triage
test since it has been demonstrated to identify suspicious
lesions that frequently results in the detection of a higher
Gleason score (GS) onprostate biopsy [8,9]. Conversely,men
with negative mpMRI (nMRI) findings appear to be at low
risk of harboring significant prostatic disease. Several
studies reported a high (>90%) negative predictive value
(NPV) of mpMRI to exclude csPCa [10,11], and the PROMIS
trial found an NPV of 89% for csPCa (which dropped to
72–76% when different definitions of csPCa were used)
using templatemapping biopsy as a reference standard [12],
but there is paucity of data concerning the intermediate-
and long-term follow-up of patients with nMRI. Moreover,
according to a systematic review, no definitive conclusion
about the NPV ofmpMRI can be drawn at present, as several
issues remain to be addressed. Above all, there is great
variability in PCa prevalence in contemporary literature
[13]. The aim of this study was, therefore, to assess the
outcomes of patients with nMRI for PCa and clinical follow-
up, after 7 yr of activity at our reference center.2. Patients and methods
2.1. Study design and population
After institutional review board approval of this retrospective study, the
reports of prostate mpMRI studies performed between January 2010 and
May 2015 were reviewed. Standards for Reporting Diagnostic Accuracy
guidelines were followed [14]. A proportion of the study population was
included in a previous analysis [9]. Our patient selection criteriawere the
availability of mpMRI examinations of the prostate performed at our
institution. Overall, 4952 consecutive patients with suspicion of PCa,
based on elevated PSA levels, family history, or DRE, underwent mpMRIas per institution protocol. Among them, there were biopsy-naïve men,
patients with previous negative biopsies, and patients on AS protocols.
Reports of men with nMRI were reviewed and considered for this study.
Two main subgroups were identified: group A included naïve men and
group B included men with previous negative biopsy. A proportion of
patents in group A underwent SB straight after imaging, while the
remaining did not. All patients were followed with serial PSA
measurements and DRE, under the supervision of a multidisciplinary
team (MDT) and underwent repeat biopsy (group B and those in group A
who underwent SB after the first nMRI) or SB (patients in group A who
did not receive SB straight after imaging) when clinically indicated. In
particular, patients in group A with no biopsy after the first nMRI
underwent SB if there was still high clinical suspicion based on high or
rising PSA/PSA density (PSAD) levels and/or other clinical features
(family history, young age, and DRE). In absence of these concerns,
patients were counseled about the potential risks of both under- and
overdiagnosis. In most of the cases, the final decision to omit biopsy was
a patient’s preference. Patients in both groups were included in the
analysis to assess the risks of developing any-grade PCa and csPCa after
nMRI if they had at least a second nMRI (8–12 mo apart from the first)
and a minimum MDT follow-up of 24 mo at our center, except for
patients who were diagnosed with PCa after the first nMRI.
Reports of men with positive or uncertain mpMRI studies were also
reviewed to assess PCa prevalence in our population, cancer detection
rate of mpMRI, and its positive predictive value.
2.2. Multiparametric MRI imaging protocol
MRI of the pelvis, focused on the prostate gland, was performed using a
3-T magnet equipped with a phased-array coil and an endorectal coil
(EC). The ECwas progressively used less, in favor of a 32-channel phased-
array coil, since images with comparable quality could be obtained
[15]. Details about imaging protocol and use of EC are listed in
Supplementary Table 1.
2.3. Multiparametric MRI interpretation
The images were evaluated in consensus by two genitourinary
radiologists, with 13 and 2 yr of experience at the beginning of the
study period. Starting from2012,mpMRI studieswere assessed using the
Prostate Imaging Reporting and Data System (PI-RADS) score [16],
according to which an examination is considered negative when
assigned a score of 1 or 2. Examinations performed earlier were
classified as negativewhen the report stated that no suspicious focuswas
found. Quantitative analysis was not considered as part of the definitive
report since it was not performed in all patients.
2.4. Prostate biopsy and csPCa definition
Patients with nMRI in group A underwent standard SB, with 12–18 cores
(median 14) biopsied for each patient, within 30 d from the first nMRI or
as soon as indicated by MDT. Patients in group B underwent repeat
saturation biopsy when indicated. Patients with uncertain or positive
mpMRI results underwent SB with additional cognitive fusion-targeted
biopsy cores on suspicious areas, mpMRI-targeted biopsy using a
transrectal ultrasound/MRI fusion biopsy system or in-bore mpMRI-
guided biopsy, within 30 d from mpMRI.
According to EAU-ESTRO-SIOG guidelines [1], selection criteria for
insignificant cancer, eligible for AS, included the following: GS 6, clinical
stage T1c or T2a, PSA <10 ng/ml, PSAD <0.15 ng/ml, and fewer than two
to three positive cores with <50% cancer involvement on each positive
core. After radical prostatectomy (RP), PCa was defined as low risk if
stage was pT2c or lower, GS <7, and tumor volume <0.5 cm3 [17].
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To assess any-grade PCa and csPCa diagnosis-free survival probabilities
in both groups, a Kaplan-Meier analysis was performed. Any-grade PCa
and csPCa diagnosis-free survival was calculated from the date ofmpMRI
examination to the diagnosis of PCa or censored at the last follow-up
evaluation (at least 24 mo after the first nMRI). Univariable and
multivariable Cox regression models were used to identify independent
predictors of subsequent diagnosis of csPCa.
All data were analyzed using the Statistical Package for Social Science
(SPSS; ver. 22.0; SPSS Inc., IBM Corp; Armonk, NY, USA). All statistical
analyses were two sided and statistical significancewas defined as p< 0.05.3. Results
3.1. Study population
During the study period, 1545 (31%) of all patients
underwent nMRI; 290 (19%) of these were excluded for
various reasons (Fig. 1). A total of 1255menwith nMRI were
enrolled, 659 (53%) in group A, and 596 (47%) in group B.
Table 1 summarizes clinical characteristics of each group.[(Fig._1)TD$FIG]
Fig. 1 – Flowchart of study design. AS = active surveillance; csPCa = clinically sig
up; MDT = multidisciplinary team; mpMRI = multiparametric magnetic resonan
NPV = negative predictive value; PCa = prostate cancer; PSA = prostate-specific a
TB = template saturation biopsy.As for the remaining mpMRI reviewed, 3407 had
uncertain or positive findings at imaging; of these, 985
(29%) were not followed at our institution. The clinical
characteristics and biopsy outcome of the remaining
2422 were collected in a START-consistent database [18]
and are listed in Supplementary Table 2.
3.2. Biopsy and follow-up outcomes
In group A, 395/659 (60%) underwent SB within 30 d after
initial nMRI and 12 patients were diagnosed with PCa, all
being csPCa. After a median follow-up of 38 (interquartile
range [IQR] 29–48) mo, 85 any-grade PCa cases were
diagnosed in group A, with 36 being csPCa (Fig. 2). The
24 csPCa cases diagnosed in this subgroup during follow-up
were found in the 264/659 (40%) menwho did not undergo
SB after the first nMRI in group A. After a median follow-up
of 60 (IQR 48–70) mo, 78 any-grade PCa cases were
diagnosed in group B, with 24 being csPCa.
Any-grade PCa diagnosis-free survival probability at
24mowas 94% in group A and 96% in B; at 48mo, it was 84%
in groupA and 96% in group B (Fig. 3A). CsPCa diagnosis-freenificant prostate cancer; DRE = digital rectal examination; FU = follow-
ce imaging of the prostate; nMRI = negative mpMRI examination;
ntigen; SB = systematic transrectal ultrasound-guided biopsy;
Table 1 – Baseline clinical and demographic data, and follow-up length of the two subgroups
Variable A: naïve patients (n = 659) B: patients with previous negative SB (n = 596)
Age 66 (62–69) 68 (60–72)
PSA (ng/ml) 5.9 (3.9–7.6) 5.6 (3.2–7.8)
Prostate volume on MRI (ml) 50 (42–68) 60 (38–73)
PSA density 0.11 (0.08–0.14) 0.10 (0.08–0.15)
Family history, n (%) 71 (11) 44 (7)
Positive DRE 64 (10) 54 (9)
Follow-up (mo) 38 (29–48) 60 (48–78)
DRE = digital rectal examination; MRI = magnetic resonance imaging; PSA = prostate-specific antigen; SB = systematic transrectal ultrasound-guided prostate
biopsy.
[(Fig._2)TD$FIG]
Fig. 2 – Naïve 60-yr-old man with a PSA of 6.9 ng/ml. (A) T2-weighted sequence from mpMRI examination shows a circumscribed basal hypointense
focus, which may be consistent with central zone appearance. (B) Perfusion color map does not show early enhancement corresponding to the focal
finding on T2-weighted imaging. (C) Apparent diffusion coefficient map and (D) diffusion-weighted imaging with b value set at 2000 s/mm2 failed to
show suspicious areas at the same level. According to PI-RADS version 2, the overall score should be 2. This patient, because of rising PSA (7.8 after
3 mo), underwent standard systematic transrectal ultrasound-guided biopsy, which showed a left posterolateral paramedian microfocus of prostate
cancer (Gleason score 4 + 4). (E and F) The patient underwent radical prostatectomy, which showed a paramedian posterior adenocarcinoma of the
prostate with invasion of seminal vesicles, which corresponded to the suspicious area on T2-weighted imaging. Final diagnosis was as follows:
adenocarcinoma of the prostate, Gleason score 9 (5 + 4), pT3b, pN1—group V. Plausible reason for false negative at mpMRI was predominant cribriform
morphology. mpMRI = multiparametric magnetic resonance imaging of the prostate; PI-RADS = Prostate Imaging Reporting and Data System;
PSA = prostate-specific antigen.
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in group B; at 48 mo, the values remained unchanged
(Fig. 3B).
After a median follow-up of 52 (IQR 37–68) mo (entire
cohort), there were no cases of disease progression and no
patient died because of PCa. Median follow-up for patients
who were not diagnosed with any-grade PCa was 39 (IQR
30–48) mo in group A and 61 (IQR 49–71) mo in group B.
Median follow-up for patients who were not diagnosedwith csPCa was 39 (IQR 30–48) mo in group A and 60 (IQR
48–78) mo in group B.
Clinical and cancer characteristics of all patients diag-
nosed with csPCa, including possible reasons of nMRI in
patients undergoing RP, are listed in Table 2.
On univariable analysis, age, PSA, PSAD, and previous
negative biopsy were significant predictors of subsequent
csPCa diagnosis in men with nMRI. On multivariable Cox
regression analysis, all these variables except for the
[(Fig._3)TD$FIG]
Fig. 3 – Kaplan-Meier analysis for the two subgroups: (A) any-grade PCa diagnosis-free survival function and (B) clinically significant PCa diagnosis-
free survival function. Bpx = biopsy; Neg = negative; PCa = prostate cancer; SE = standard error.
Table 2 – Clinical characteristics and biopsy or radical
prostatectomy outcome of patients with clinically significant
prostate cancer and negative multiparametric MRI
Patients with nMRI diagnosed with csPCa (n = 60)
Median (IQR) age (yr) 64 (58–67)
Median (IQR) PSA level (ng/ml) 7.3 (6.2–8.8)
Median (IQR) prostate volume on MRI (ml) 48 (32–58)
Median (IQR) PSA density (ng/ml/ml) 0.16 (0.13–0.27)
Gleason score, n (%)
6 7 (12)
3 + 4 25 (42)
4 + 3 18 (30)
8 10 (16)
Patients undergoing RP, n (%) 36 (60)
Reason for false negative, n (%)
BPH 11 (31)
Prostatitis 5 (14)
Small (0.5 ml) tumor in anterior horn 11 (31)
Mucinous adenocarcinoma 1 (2)
Predominant cribriform morphology 8 (22)
BPH = benign prostatic hyperplasia; csPCa = clinically significant prostate
cancer; IQR = interquartile range; MRI = magnetic resonance imaging;
PSA = prostate-specific antigen; RP = radical prostatectomy.
Table 3 – Multivariable Cox regression analysis to identify
predictors of subsequent PCa diagnosis in patients with a previous
negative mpMRI
Variables HR 95% CI p value
PSA 1.21 1.1–1.32 <0.001
PSAD 7.57 2.73–21 <0.001
Previous negative SB 1.01 0.53–1.93 0.97
Age 0.93 0.89–0.98 0.005
CI = confidence interval; HR = hazard ratio; mpMRI = multiparametric
magnetic resonance imaging of the prostate; PCa = prostate cancer;
PSA = prostate-specific antigen; PSAD = PSA density; SB = systematic
biopsy.
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(Table 3).
3.3. Positive mpMRI outcomes
Of the 2422 patients with positive mpMRI results, 1827
(75%) were diagnosed with PCa and 1103 (46%) had csPCa.
The prevalence of csPCawas 32%. Biopsy results are listed in
Supplementary Table 2.
4. Discussion
Multiparametric MRI of the prostate has earned its role in
the setting of targeting biopsy after a first negative SB [1]
thanks to intense investigation [10,19,20] in the past decade.
However, it is still unclear if its NPV is sufficiently high to
possibly avoid biopsy in men with nMRI.Several studies attempted to validate the clinical utility
of nMRI. Villers et al [21] reported NPVs of 85% and 95% for
foci >0.2 and >0.5 cm3, respectively, compared with
histopathology. Subsequent studies reported a “clinical
NPV” for csPCa of 90% at 5-yr follow-up after initial nMRI
and of 99% in men undergoing mpMRI before SB [11,22]. A
recent meta-analysis showed that mpMRI has a median
NPV of 88% for csPCa, for amedian detection rate of csPCa of
33% [13]. Nevertheless, several crucial issues for a more
definitive assessment of NPV remain to be addressed, with
the great variability in csPCa prevalence among the
different cohorts (which directly influences NPV), the lack
of standardization of the population referred to prostate
biopsy, and the variability of definitions of csPCa beingmost
important.
According to other authors, mpMRI does not have a very
high NPV. Filson et al [23] reported an NPV of nMRI of 54%,
with 16% of men in their cohort (38/244) being diagnosed
with csPCa. However, 48% (116/244) of their patients had a
history of positive biopsy. Another report showed that 60%
of patients with nMRI studies had unfavorable pathology
after RP [24]. Nonetheless, all patients in that cohort
underwent RP, with possible selection bias.
Our retrospective study after 7 yr of clinical experience
showed that any-grade PCa and csPCa diagnosis-free
survival were both 96% in men with nMRI and previous
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outcome strengthens previous findings [8,11,22] that
showedmpMRI to be highly reliable in excluding significant
disease in men with previous negative biopsy and are in
accordance with the findings of the more recent papers by
Ahmed et al [12] and Schouten et al [25]. On the contrary, in
naïve patients (group A), all PCa and csPCa diagnosis-free
probabilities at 48 mo were 84% and 95%, respectively,
showing that the addition of SB improves all PCa and csPCa
diagnosis-free survival from 84% to 96% and from 95% to
96%, respectively. However, on multivariable analysis, a
previous negative SB was not an independent predictor of
subsequent csPCa diagnosis, while age, PSA, and PSAD were
all independent predictors, with PSAD being the strongest
(hazard ratio: 7.57). Moreover, csPCa diagnosis-free survival
probabilities were not significantly different in the two
groups. From a clinical standpoint, an SB can be considered
after an nMRI in patients with high PSA and PSAD; this is
consistent with the findings of a previous research
[26]. Besides, a 5% risk of developing a csPCa during
follow-up, compared with a reported NPV of SB of 74% or
lower[12], might be considered acceptable and clinically
appropriate, and would prompt PSAmonitoring rather than
biopsy as a reasonable argument for patients’ counseling.
With regard to clinical and pathologic features of csPCa
developed after nMRI in patients who underwent RP, we
found, as previously reported, that prostatitis and benign
prostatic hyperplasia can mask PCa [22] and that small
tumors near the anterior horn can bemissed atmpMRI [27],
possibly indicating that the reader experience is extremely
important to avoid false negative, as also shown by the
PROMIS trial, which was based on quality control of mpMRI
and systematic training of radiologists [12].
Finally, the relatively high frequency of high-grade PCa
with cribriform morphology in patients with nMRI who
underwent RP highlights the limitations of current prostate
mpMRI. According to recent reports [28], PCa with
predominant cribriform morphology is often invisible at
imaging, and mucinous adenocarcinoma, although rarer, is
also not readily visible on diffusion-weighted imaging [29],
which is considered the “dominant sequence” by PI-
RADSv2. In this regard, quantitative analysis, although
not considered in the present study, has shown promising
results in peripheral zone tumor characterization [30].
The major strengths of our study are the large patient
population included in the analysis and the “real-life”
setting, since our data are based on image interpretation
performed during clinical routine. The use of at least one
confirmatory nMRI is also pivotal, as without it a substantial
proportion of men (at least 20%) would have undergone
repeat biopsy, with limited csPCa detection rate (12%),
according to a contemporary series [6].
This study has several limitations. First of all, a “true”
NPV could not be calculated because of the inherent limits
of this approach:where nowholemount of the prostatewas
done, in the majority of patients, no true negative can exist.
Besides, not all patients underwent prostate biopsy, this
decision being supported by an MDT, which is not always
available in clinical routine. A possible selection bias in thissense could havemaximized the detection of csPCa. Second,
as not all patientswith positivempMRIwere followed at our
center, the true prevalence of PCa of the original cohort
could not be assessed. Finally, in populations with a higher
prevalence of csPCa, in cohorts with longer follow-up, and
when other definitions of csPCa are applied, the risk of
csPCa development may be underestimated.
5. Conclusions
In our study, we demonstrated that csPCa diagnosis-free
survival probability after 48 mo of follow-up was 95% and
96% in naïve men and patients with previous negative
biopsy, respectively. As a result, after an nMRI, a noninvasive
follow-up based on confirmatory MRI and PSA measure-
ments is a viable option for selected patients. Nevertheless,
SB cannot be routinely omitted after nMRI, especially in
younger patients with strong clinical suspicion of PCa
(rising PSAD), given the possibility of missing clinically
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